2 transcripts
URGN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
with previous clinical trials in UGN-102. Adverse events were, in general, mild and moderate in severity. The vast majority were lower urinary tract
URGN
Earnings call transcript
NASDAQ
2023 Q4
14 Mar 24
transformative and the major growth driver for UroGen have approved, future research and development efforts for UGN-103, UGN-104 and UGN-301, our corporate
- Prev
- 1
- Next